NCT06672068View on ClinicalTrials.gov

A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions
NSCLC
Interventions
DRUG

TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin

TY-9591 80mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）

DRUG

TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin

TY-9591 160mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）

All Listed Sponsors
lead

TYK Medicines, Inc

INDUSTRY